Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

BACKGROUND: Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody–drug conjugate depatuxizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassman, Andrew B, van den Bent, Martin J, Gan, Hui K, Reardon, David A, Kumthekar, Priya, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B, Papadopoulos, Kyriakos P, Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M, Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Ansell, Peter J, Bain, Earle, Holen, Kyle D, Maag, David, Merrell, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303422/
https://www.ncbi.nlm.nih.gov/pubmed/29982805
http://dx.doi.org/10.1093/neuonc/noy091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303422/
https://www.ncbi.nlm.nih.gov/pubmed/29982805
http://dx.doi.org/10.1093/neuonc/noy091

Ejemplares similares